July 24, 2013

Even though customers may only buy certain OTC categories a few times a year, for consumer healthcare brands, the opportunities to have a more meaningful relationship in the lives of their consumers has never been greater, Stefan Merlo, director of healthcare strategy, Novartis Consumer Health, told DSNtv in a special edition of DSN Executive Viewpoints.

September 4, 2015

Ancino this week launched its rivastigmine patch, a generic version of the Exelon patch.

September 3, 2015

 The drug, a biosimilar version of Amgen’s Neupogen, is the first biosimilar drug to launch in the U.S.

September 2, 2015

The collaboration will see them working on a BACE inhibitor program to treat Alzheimer’s disease and developing Amgen’s migraine drugs.

September 2, 2015

Sandoz on Wednesday introduced rivastigmine transdermal system, a generic version of Exelon Patch1, in the United States.

August 28, 2015

Perrigo announced Friday that it had completed its $224 million (€200 million) acquisition of several OTC brands from GlaxoSmithKline’s OTC portfolio.

August 25, 2015

The drug can be used in children 1 year of age and older with ITP who have not had a sufficient response to a splenectomy, immunoglobulins or corticosteroids.

August 11, 2015

Todd Hutsko is departing GlaxoSmithKline Consumer Healthcare for Fleet Laboratories, where he will be VP sales. 

July 24, 2015

The Food and Drug Administration announced Friday that it had approved Novartis’ Odomzo (sonidegib). The drug is meant to treat basal cell carcinoma, the most common form of advanced skin cancer.

July 22, 2015

Novartis will be able to introduce Sandoz’s Zarxio (filgrastim) after Sept. 2, the U.S. Court of Appeal for the Federal Circuit ruled Wednesday. 

June 24, 2015

Aurobindo Pharma Limited has announced that it has received final approval from the U.S. Food and Drug Administration for entacapone tablets USP, 200 mg, the generic equivalent to Comtan Tablets 200 mg.

June 12, 2015

The drug is a daily oral treatment for children 6 and up with chronic immune thrombocytopenia (ITP).

June 2, 2015

Perrigo's new OTC product portfolio acquired out of the GSK/Novartis joint venture are sold primarily throughout Europe and Brazil. 

May 7, 2015

Drug Store News on Sunday caught up with Brian McNamara, region head of Europe and the Americas of the recently christened GSK Consumer Healthcare, representing the joint venture between GlaxoSmithKline and Novartis to talk about what a consolidating OTC market means for the industry, and how GSK will be coming to market.

May 7, 2015

Kline reports OTC growth of 1.4% to more than $24 billion. 

April 24, 2015

Sandoz on Friday announced the launch of levoleucovorin injection ready-to-use single use vial, a generic version of Fusilev, which is marketed by Spectrum Pharmaceuticals. 

April 16, 2015

Sandoz on Thursday introduced a new generic MS therapy.

April 14, 2015

Ducere Pharma relaunched Cruex as a fungal nail revitalizing gel on Tuesday. 

April 14, 2015

Diplomat Pharmacy announced it will distribute Novartis' new medicine Jadenu, which is indicated to treat patients with chronic iron overload. 

March 31, 2015

Teva Pharmaceutical Industries announced the launch of generic Exforge (amlodipine and valsartan) tablets, which are indicated for the treatment of hypertension. 


March 13, 2015

Colgate announces changes to its board of directors, including the resignation of Joseph Jimenez, CEO of Novartis.

March 4, 2015

While the big four analgesic manufacturers — Bayer, Pfizer, McNeil and Novartis — command the lion’s share of retail ad support behind their mega analgesic brands, Prestige Brands and BedRock Brands are making headway promoting their niche pain relieving products.

February 27, 2015

GlaxoSmithKline expects to complete its Novartis transaction in the week commencing March 2.

February 26, 2015

The CDC’s Advisory Committee on Immunization Practices made a unanimous recommendation for use of meningococcal group B vaccines to vaccinate high-risk groups in the United States.